1. Market Research
  2. > Proteinuria – Pipeline Review, H1 2013

Proteinuria – Pipeline Review, H1 2013

  • May 2013
  • -
  • Global Markets Direct
  • -
  • 37 pages

Proteinuria – Pipeline Review, H1 2013

Summary

Global Markets Direct’s, 'Proteinuria - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Proteinuria, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Proteinuria. Proteinuria - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Proteinuria.
- A review of the Proteinuria products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Proteinuria pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Proteinuria.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Proteinuria pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Proteinuria - Pipeline Review, H1 2013
Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Proteinuria Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Proteinuria 7
Proteinuria Therapeutics under Development by Companies 9
Proteinuria Therapeutics under Investigation by Universities/Institutes 10
Late Stage Products 11
Comparative Analysis 11
Mid Clinical Stage Products 12
Comparative Analysis 12
Pre-Clinical Stage Products 13
Comparative Analysis 13
Proteinuria Therapeutics - Products under Development by Companies 14
Proteinuria Therapeutics - Products under Investigation by Universities/Institutes 15
Companies Involved in Proteinuria Therapeutics Development 16
Questcor Pharmaceuticals, Inc. 16
FibroGen, Inc. 17
Isotechnika Pharma Inc. 18
InVasc Therapeutics, Inc. 19
Proteinuria - Therapeutics Assessment 20
Assessment by Monotherapy Products 20
Assessment by Route of Administration 21
Assessment by Molecule Type 23
Drug Profiles 25
FG-3019 - Drug Profile 25
Product Description 25
Mechanism of Action 25
RandD Progress 25
adalimumab - Drug Profile 27
Product Description 27
Mechanism of Action 27
RandD Progress 27
INV-141 - Drug Profile 28
Product Description 28
Mechanism of Action 28
RandD Progress 28
corticotropin zinc hydroxide - Drug Profile 29
Product Description 29
Mechanism of Action 29
RandD Progress 29
INV-142 - Drug Profile 30
Product Description 30
Mechanism of Action 30
RandD Progress 30
paricalcitol - Drug Profile 31
Product Description 31
Mechanism of Action 31
RandD Progress 31
Proteinuria Therapeutics - Drug Profile Updates 32
Proteinuria Therapeutics - Dormant Products 34
Proteinuria - Product Development Milestones 35
Featured News and Press Releases 35
Dec 16, 2010: Evolva Begins Multiple Ascending Dose Study With EV-077 35
Appendix 36
Methodology 36
Coverage 36
Secondary Research 36
Primary Research 36
Expert Panel Validation 36
Contact Us 37
Disclaimer 37



List of Tables

Number of Products Under Development for Proteinuria, H1 2013 7
Products under Development for Proteinuria - Comparative Analysis, H1 2013 8
Number of Products under Development by Companies, H1 2013 9
Number of Products under Investigation by Universities/Institutes, H1 2013 10
Comparative Analysis by Late Stage Development, H1 2013 11
Comparative Analysis by Mid Clinical Stage Development, H1 2013 12
Comparative Analysis by Pre-Clinical Stage Development, H1 2013 13
Products under Development by Companies, H1 2013 14
Products under Investigation by Universities/Institutes, H1 2013 15
Questcor Pharmaceuticals, Inc., H1 2013 16
FibroGen, Inc., H1 2013 17
Isotechnika Pharma Inc., H1 2013 18
InVasc Therapeutics, Inc., H1 2013 19
Assessment by Monotherapy Products, H1 2013 20
Assessment by Stage and Route of Administration, H1 2013 22
Assessment by Stage and Molecule Type, H1 2013 24
Proteinuria Therapeutics - Drug Profile Updates 32
Proteinuria Therapeutics - Dormant Products 34



List of Figures

Number of Products under Development for Proteinuria, H1 2013 7
Products under Development for Proteinuria - Comparative Analysis, H1 2013 8
Products under Development by Companies, H1 2013 9
Products under Investigation by Universities/Institutes, H1 2013 10
Late Stage Products, H1 2013 11
Mid Clinical Stage Products, H1 2013 12
Pre-Clinical Stage Products, H1 2013 13
Assessment by Monotherapy Products, H1 2013 20
Assessment by Route of Administration, H1 2013 21
Assessment by Stage and Route of Administration, H1 2013 22
Assessment by Molecule Type, H1 2013 23
Assessment by Stage and Molecule Type, H1 2013 24

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.